TriangleNCT02420795 · OUTCOME
Progression-free Survival (PFS)- (Phase 2)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- weeks
- Interval / dispersion
- Full Range
- Time frame
- every 3 months for 1 year, then every 6 months, up to 6 years
What was measured
Progression free survival is defined as time in weeks from start of study treatment to first documentation of objective tumor progression or up to death due to any cause, whichever occurs first.
Groups in this outcome
ONC201 625 mg
Patients receive Akt/ERK inhibitor ONC201 625 mg PO every 7 days. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
| Group | Source count |
|---|---|
| ONC201 625 mg | 5 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| ONC201 625 mg | 5 | Not reported | 1 | 10 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 1
- upper Limit
- 10
- value
- 5
- denoms
- counts
- group Id
- OG000
- value
- 5
- units
- Participants
- description
- Progression free survival is defined as time in weeks from start of study treatment to first documentation of objective tumor progression or up to death due to any cause, whichever occurs first.
- dispersion Type
- Full Range
- groups
- description
- Patients receive Akt/ERK inhibitor ONC201 625 mg PO every 7 days. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
- id
- OG000
- title
- ONC201 625 mg
- param Type
- MEDIAN
- reporting Status
- POSTED
- time Frame
- every 3 months for 1 year, then every 6 months, up to 6 years
- title
- Progression-free Survival (PFS)- (Phase 2)
- type
- SECONDARY
- unit Of Measure
- weeks
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice